Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced it will release its third quarter fiscal year 2024 financial results on November 6, 2024, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. A press release with financial results will be distributed before the call. The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information.
Sera Prognostics (NASDAQ: SERA), conosciuta come The Pregnancy Company®, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre dell'anno fiscale 2024 il 6 novembre 2024, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica e un webcast alle 17:00, ora orientale, per discutere i punti salienti operativi, i risultati finanziari e argomenti chiave. Un comunicato stampa con i risultati finanziari sarà distribuito prima della chiamata. L'azienda si concentra sul miglioramento della salute materna e neonatale attraverso informazioni innovative sui biomarker della gravidanza.
Sera Prognostics (NASDAQ: SERA), conocida como The Pregnancy Company®, ha anunciado que publicará sus resultados financieros del tercer trimestre del año fiscal 2024 el 6 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast a las 5:00 p.m., hora del Este, para discutir los aspectos operativos, los resultados financieros y temas clave. Un comunicado de prensa con los resultados financieros se distribuirá antes de la llamada. La empresa se centra en mejorar la salud materna y neonatal a través de información innovadora sobre biomarcadores del embarazo.
Sera Prognostics (NASDAQ: SERA)는 The Pregnancy Company®로 알려져 있으며, 2024 회계년도 3분기 재무 결과를 2024년 11월 6일 시장 마감 후 발표할 것이라고 밝혔습니다. 이 회사는 동부 표준시 기준 오후 5시에 운영 주요 사항, 재무 결과 및 핵심 주제에 대해 논의하기 위한 컨퍼런스 콜과 웹캐스트를 주최할 예정입니다. 호출 전에 재무 결과가 포함된 보도 자료가 배포됩니다. 이 회사는 혁신적인 임신 바이오마커 정보를 통해 모성과 신생아 건강을 개선하는 데 집중하고 있습니다.
Sera Prognostics (NASDAQ: SERA), connue sous le nom de The Pregnancy Company®, a annoncé qu'elle publierait ses résultats financiers du troisième trimestre de l'exercice 2024 le 6 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webcast à 17h00, heure de l'Est, pour discuter des points saillants opérationnels, des résultats financiers et des sujets clés. Un communiqué de presse contenant les résultats financiers sera distribué avant l'appel. L'entreprise se concentre sur l'amélioration de la santé maternelle et néonatale grâce à des informations innovantes sur les biomarqueurs de grossesse.
Sera Prognostics (NASDAQ: SERA), bekannt als The Pregnancy Company®, hat angekündigt, dass es am 6. November 2024, nach Marktabschluss, seine finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2024 bekannt geben wird. Das Unternehmen wird um 17:00 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um betriebliche Highlights, finanzielle Ergebnisse und wichtige Themen zu besprechen. Eine Pressemitteilung mit finanziellen Ergebnissen wird vor dem Anruf verteilt. Das Unternehmen konzentriert sich darauf, die Mutter- und Neugeborenen-Gesundheit durch innovative Informationen zu Schwangerschaftsbiomarkern zu verbessern.
- None.
- None.
Conference Call Details:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/L6rDpZAVdM8
Live audio of the webcast will be available online from the Investors page of the Company's website at www.seraprognostics.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City,
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2023 March of Dimes Report Card shows that, for the last five consecutive years, more than one in ten infants is born prematurely in the
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date, time and content of the Company's quarterly earnings release and conference call; and the company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; the COVID-19 pandemic and its potential lingering impact on our operations, as well as the business or operations of third parties with whom we conduct business; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Final Prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-third-quarter-fiscal-year-2024-financial-results-on-november-6-2024-302287821.html
SOURCE Sera Prognostics, Inc.
FAQ
When will Sera Prognostics (SERA) report Q3 2024 earnings?
How can I access Sera Prognostics (SERA) Q3 2024 earnings call?
What time is Sera Prognostics (SERA) Q3 2024 earnings call?
